Practitioner's Docket No. MPI98-148P1USRCE2M

U.S.S.N. 09/673,302

REMARKS

Herein is an Amendment and Response to the Office action mailed October 19, 2004. Applicants thank the Examiner for withdrawing the finality of the previous Office action, for entering Applicants' amendment filed July 23, 2004 and for indicating that claims 79-81 and 94-99 are allowable. In this Amendment and Response, Applicants cancel claims 76-78, 82 and 91 and amend claims 83-85, 87-89, 93 and 99. Claims 79-81, 83-90 and 93-99 are pending. The Examiner's remarks in the Office action are addressed in the sections below.

Double Patenting

The Examiner noted that claims 90 and 91 are substantial duplicates and that one claim would objected to if the other were to be found allowable. Applicants have canceled claim 91.

Rejection of Claims Under 35 U.S.C. §112, First Paragraph

Claims 76-78, 82-91 and 93 were rejected under 35 U.S.C. §112, first paragraph, as being enabling only for a transgenic mouse comprising a transgene integrated into the genome wherein the transgene comprises DNA encoding a mutant GP IIIa (beta3) protein having two, not one, conservative amino acid substitutions for two wild type tyrosine residues in its mutant cytoplasmic domain. Applicants have canceled claims 76-78, 82 and 91, thereby obviating the rejection on these claims. Without acquiescing, in the interest of progressing prosecution of this application, Applicants have amended claims 83-85 and 87-89 to recite the substitution of two tyrosine residues in the cytoplasmic domain of GP IIIa (beta3) protein. Furthermore, applicants have amended claim 93 to make claim 93 dependent on allowed claim 79. Accordingly, Applicants have changed the dependency of claim 99 from claim 79 to claim 96. In view of these amendments, Applicants respectfully request that the rejection of claims 83-90 and 93 be withdrawn.

Conclusion

The foregoing amendments and remarks are being made to place the Application in condition for allowance. Applicants respectfully request the timely allowance of the pending claims because, in view of these amendments and remarks, Applicants respectfully submit that the rejections of the claims U.S.C. §112 are herein overcome. Applicants believe that this application is now in condition for allowance. Early notice to this effect is solicited.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned. If the Examiner disapproves of

(Page 7 of 8)

Practitioner's Docket No. MPI98-148P1USRCE2M

U.S.S.N. 09/673,302

Applicants amendments and remarks in this response, Applicants request a prompt mailing of a notice to that effect.

This paper is being filed timely as a request for a one month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

10 February 2005

MILLENNIUM PHARMACEUTICALS, INC.

Tracy M. Sioussat, Ph.D.

Registration No. 50,609 40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820